Sarah A Henry1, Anna E Prizment, Kristin E Anderson. 1. Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, University of Minnesota Masonic Cancer Center, Minneapolis, MN 55455, USA.
Abstract
CONTEXT: Studies have shown a relationship between history of diabetes and the risk of pancreatic cancer; however, the temporal relation between diabetes and pancreatic cancer is not clearly established. OBJECTIVES: Diabetes and diabetes duration were examined in relation to pancreatic cancer in a population-based case-control study and prospective cohort. METHODS: Case-control study: pancreatic cancer cases (n=200) from the Midwest were frequency matched by age and sex to population controls (n=673). Logistic regression yielded odds ratios (ORs) and 95% confidence intervals (95% CI). Iowa Women's Health Study (IWHS) cohort: 292 incident pancreatic cancer cases occurred between 1986-2008 among 36,084 post-menopausal, initially cancer-free women. Diabetes status and diagnosis age were ascertained at baseline and follow-ups. Proportional hazards regression yielded hazard ratios (HR, 95% CI) for pancreatic cancer in relation to baseline diabetes. Time-dependent analyses accounted for diabetes diagnosed after baseline. A nested-case control analysis assessed diabetes duration as a risk factor. RESULTS: In the case-control study, compared to participants without diabetes, the multivariate ORs (95% CI) for pancreatic cancer were 2.35 (1.24-4.47) for those with diabetes and 4.00 (0.94-16.9), 2.79 (0.97-8.04), and 2.40 (0.97-5.98) for diabetes durations of 2-5 years, 5.1-10 years, and more than 10 years, respectively. In IWHS, compared to no diabetes, multivariate-adjusted HRs for pancreatic cancer were 1.86 (1.23-2.83) for baseline diabetes and 1.94 (1.40-2.69) adding diabetes during follow-up. In an IWHS nested case-control analysis, ORs were 1.70 (0.78-3.67), 2.62 (1.48-4.65), and 2.10 (1.36-3.24) for diabetes durations of 2-5 years, 5.1-10 years and more than 10 years, respectively, versus no diabetes. CONCLUSIONS: Diabetes is associated with pancreatic cancer risk and this is similar across different duration categories.
CONTEXT: Studies have shown a relationship between history of diabetes and the risk of pancreatic cancer; however, the temporal relation between diabetes and pancreatic cancer is not clearly established. OBJECTIVES:Diabetes and diabetes duration were examined in relation to pancreatic cancer in a population-based case-control study and prospective cohort. METHODS: Case-control study: pancreatic cancer cases (n=200) from the Midwest were frequency matched by age and sex to population controls (n=673). Logistic regression yielded odds ratios (ORs) and 95% confidence intervals (95% CI). Iowa Women's Health Study (IWHS) cohort: 292 incident pancreatic cancer cases occurred between 1986-2008 among 36,084 post-menopausal, initially cancer-free women. Diabetes status and diagnosis age were ascertained at baseline and follow-ups. Proportional hazards regression yielded hazard ratios (HR, 95% CI) for pancreatic cancer in relation to baseline diabetes. Time-dependent analyses accounted for diabetes diagnosed after baseline. A nested-case control analysis assessed diabetes duration as a risk factor. RESULTS: In the case-control study, compared to participants without diabetes, the multivariate ORs (95% CI) for pancreatic cancer were 2.35 (1.24-4.47) for those with diabetes and 4.00 (0.94-16.9), 2.79 (0.97-8.04), and 2.40 (0.97-5.98) for diabetes durations of 2-5 years, 5.1-10 years, and more than 10 years, respectively. In IWHS, compared to no diabetes, multivariate-adjusted HRs for pancreatic cancer were 1.86 (1.23-2.83) for baseline diabetes and 1.94 (1.40-2.69) adding diabetes during follow-up. In an IWHS nested case-control analysis, ORs were 1.70 (0.78-3.67), 2.62 (1.48-4.65), and 2.10 (1.36-3.24) for diabetes durations of 2-5 years, 5.1-10 years and more than 10 years, respectively, versus no diabetes. CONCLUSIONS:Diabetes is associated with pancreatic cancer risk and this is similar across different duration categories.
Authors: Loren Lipworth; Antonella Zucchetto; Cristina Bosetti; Silvia Franceschi; Renato Talamini; Diego Serraino; Joseph K McLaughlin; Carlo La Vecchia; Eva Negri Journal: Diabetes Metab Res Rev Date: 2011-03 Impact factor: 4.876
Authors: Suresh T Chari; Cynthia L Leibson; Kari G Rabe; Lawrence J Timmons; Jeanine Ransom; Mariza de Andrade; Gloria M Petersen Journal: Gastroenterology Date: 2007-10-26 Impact factor: 22.682
Authors: Kristin E Anderson; Rashmi Sinha; Martin Kulldorff; Myron Gross; Nicholas P Lang; Cheryl Barber; Lisa Harnack; Eugene DiMagno; Robin Bliss; Fred F Kadlubar Journal: Mutat Res Date: 2002-09-30 Impact factor: 2.433
Authors: D T Silverman; M Schiffman; J Everhart; A Goldstein; K D Lillemoe; G M Swanson; A G Schwartz; L M Brown; R S Greenberg; J B Schoenberg; L M Pottern; R N Hoover; J F Fraumeni Journal: Br J Cancer Date: 1999-08 Impact factor: 7.640
Authors: C Bosetti; V Rosato; D Li; D Silverman; G M Petersen; P M Bracci; R E Neale; J Muscat; K Anderson; S Gallinger; S H Olson; A B Miller; H Bas Bueno-de-Mesquita; G Scelo; V Janout; I Holcatova; P Lagiou; D Serraino; E Lucenteforte; E Fabianova; P A Baghurst; W Zatonski; L Foretova; E Fontham; W R Bamlet; E A Holly; E Negri; M Hassan; A Prizment; M Cotterchio; S Cleary; R C Kurtz; P Maisonneuve; D Trichopoulos; J Polesel; E J Duell; P Boffetta; C La Vecchia; P Ghadirian Journal: Ann Oncol Date: 2014-07-23 Impact factor: 32.976
Authors: Niharika P Patel; Anna E Prizment; Bharat Thyagarajan; Evan Roberts; Heather H Nelson; Timothy R Church; DeAnn Lazovich Journal: Ann Allergy Asthma Immunol Date: 2018-04-06 Impact factor: 6.347
Authors: Albert J Farias; Anna H Wu; Jacqueline Porcel; Loïc Le Marchand; Lynne R Wilkens; Kristine R Monroe; Gertraud Maskarinec; Stephen J Pandol; Veronica Wendy Setiawan Journal: JNCI Cancer Spectr Date: 2020-05-04